Affinage

PRMT1

Protein arginine N-methyltransferase 1 · UniProt Q99873

Length
371 aa
Mass
42.5 kDa
Annotated
2026-04-28
100 papers in source corpus 49 papers cited in narrative 50 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells, catalyzing asymmetric dimethylation of arginine residues on histones and a remarkably broad range of non-histone substrates to control transcription, RNA splicing, DNA repair, innate immunity, cell cycle progression, and metabolic reprogramming. Operating through a sequential ordered Bi-Bi kinetic mechanism that requires oligomerization for full activity, PRMT1 deposits H4R3me2a marks that recruit the SWI/SNF chromatin remodeler SMARCA4 to activate gene expression and maintain chromatin accessibility at lineage-specific loci, with its genomic targeting modulated by CSNK1a1 phosphorylation and DNA-PK–dependent chromatin recruitment (PMID:32583741, PMID:14, PMID:28943242, PMID:31995759, PMID:31848151, PMID:29112789, PMID:34688662). PRMT1 methylates signaling effectors (EGFR, TBK1, CaMKII, CDK4, cGAS, SMAD7) to tune receptor activation, kinase oligomerization, cell cycle arrest, and innate immune sensing, and methylates RNA-processing factors (RBM15, SRSF1, WTAP) to regulate alternative splicing and m6A modification programs (PMID:26571401, PMID:34551290, PMID:30504773, PMID:28628091, PMID:37193698, PMID:29907569, PMID:26575292, PMID:37938975, PMID:37558663). Its catalytic output is regulated at multiple levels—redox-sensitive cysteine oxidation reversibly inhibits activity, CDK5 phosphorylation at S307 controls nucleo-cytoplasmic shuttling, and E3 ligases FBXO7 and TRIM48 target PRMT1 for proteasomal degradation—thereby coupling PRMT1 function to cellular stress and metabolic state (PMID:25911106, PMID:36995937, PMID:38839752, PMID:29186683).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1998 High

    Identification of HRMT1L2 as the human protein arginine methyltransferase ortholog of yeast Hmt1p established PRMT1 as an arginine methyltransferase with conserved function across eukaryotes.

    Evidence In vitro methyltransferase assay with recombinant protein and yeast HMT1 complementation

    PMID:9545638

    Open questions at the time
    • Substrate repertoire in human cells unknown
    • Biological function beyond methyltransferase activity uncharacterized
  2. 2008 Medium

    Discovery that TR3 orphan receptor physically inhibits PRMT1 catalytic activity while PRMT1 stabilizes TR3 independently of methylation revealed that PRMT1 has non-catalytic scaffolding functions and that its activity can be regulated by protein-protein interactions.

    Evidence Co-IP, in vitro methyltransferase inhibition assay, TR3 KO cells, reporter assay

    PMID:19095693

    Open questions at the time
    • Structural basis of TR3-mediated inhibition unresolved
    • Physiological contexts for non-catalytic PRMT1 roles not systematically explored
  3. 2015 High

    Three concurrent advances established that PRMT1 methylates diverse non-histone substrates with distinct functional outcomes: methylation of RBM15 triggers its ubiquitin-dependent degradation to reprogram splicing, methylation of EGFR extracellular domain enhances ligand binding and receptor signaling, and cysteine oxidation reversibly inactivates the enzyme, revealing redox control of its catalytic output.

    Evidence In vitro methylation, mass spectrometry, RNA-seq, site-directed mutagenesis, mouse xenograft (RBM15/EGFR); H2O2 titration with rescue (redox)

    PMID:25911106 PMID:26571401 PMID:26575292

    Open questions at the time
    • How PRMT1 selects among its many substrates in vivo unclear
    • Physiological oxidants that regulate PRMT1 in cells not defined
    • Whether EGFR extracellular methylation occurs cotranslationally or post-secretion unknown
  4. 2017 High

    Multiple studies converged to show PRMT1 as a context-dependent regulator of cell fate: it methylates CDK4 to block pre-B cell proliferation, methylates Eya1 to enable myogenic differentiation, is phosphorylated by CSNK1a1 to target proliferation genes in epidermal progenitors, and is degraded by TRIM48 to relieve ASK1 suppression; kinetic analysis defined its sequential ordered Bi-Bi catalytic mechanism.

    Evidence In vitro methylation, Co-IP, conditional KO mice (pre-B cells, muscle stem cells, epidermis), kinase assay, ChIP-seq, enzyme kinetics with synthetic peptides

    PMID:27849571 PMID:28628091 PMID:28943242 PMID:29112789 PMID:29186683

    Open questions at the time
    • How CSNK1a1 phosphorylation alters PRMT1 substrate selectivity at the structural level unknown
    • Relative contribution of processivity vs. distributive methylation in vivo unresolved
  5. 2018 High

    Tissue-specific knockouts revealed PRMT1 as essential for cardiac and bone homeostasis: it methylates CaMKII to restrain kinase activity in the heart (loss causes dilated cardiomyopathy), methylates SMAD7 to enable TGF-β/BMP signaling and EMT, interacts with GFI1 to methylate DNA repair factors MRE11/53BP1, and regulates NF-κB-driven osteoclastogenesis via p65 interaction.

    Evidence Cardiac-specific KO mice with pharmacological rescue, receptor complex Co-IP, in vitro methylation, GFI1 KO with radiation sensitivity, RANKL signaling in bone marrow macrophages

    PMID:29651020 PMID:29907569 PMID:30154485 PMID:30504773

    Open questions at the time
    • Whether CaMKII methylation occurs at specific cardiac developmental windows unknown
    • Direct structural basis of GFI1-dependent PRMT1 substrate recognition unresolved
  6. 2019 High

    PRMT1 was shown to maintain tissue identity through epigenomic programming: loss in β-cells causes immediate H4R3me2a depletion and chromatin closure at CTCF/β-cell TF sites leading to diabetes, while in skeletal muscle, PRMT1 loss triggers compensatory PRMT6-FOXO3 atrophy; additionally, PRMT1 methylates C/EBPα to displace HDAC3 and methylates ERα at R260 to activate non-genomic IGF-1 signaling.

    Evidence β-cell-specific KO with ChIP-seq/ATAC-seq, muscle-specific KO with PRMT6 epistasis, TAP-MS and mutagenesis (C/EBPα), Co-IP and signaling assays (ERα/IGF-1R)

    PMID:30653406 PMID:30692633 PMID:31015230 PMID:31848151

    Open questions at the time
    • Whether H4R3me2a loss is sufficient or requires co-loss of non-histone methylation for β-cell failure unknown
    • Cross-talk between PRMT1 and PRMT6 substrate pools not comprehensively mapped
  7. 2020 High

    DNA-PK was identified as an upstream activator that phosphorylates PRMT1 and redirects it to chromatin for H4R3me2a deposition at senescence-associated gene promoters; concurrently, PRMT1 was found to methylate EZH2 at R342 to antagonize CDK1 phosphorylation and stabilize EZH2, and to regulate epicardial EMT through Mdm4 splicing and p53-Slug degradation.

    Evidence MS proteomics, ChIP, kinase assay (DNA-PK); in vitro methylation, ubiquitination assay, xenograft (EZH2); epicardial KO with scRNA-seq (Mdm4/p53)

    PMID:31995759 PMID:32521264 PMID:32895488

    Open questions at the time
    • DNA-PK phosphorylation site(s) on PRMT1 not mapped
    • Whether EZH2 R342 methylation occurs within assembled PRC2 in vivo unknown
  8. 2021 High

    The downstream reader mechanism of H4R3me2a was clarified: SMARCA4 directly recognizes this mark to activate transcription at target loci; cancer-associated dimerization-arm mutations (W215L, Y220N, M224V) impair oligomerization and catalysis; PRMT1 also methylates SCYL1 to control COPI vesicle biogenesis and Golgi integrity, methylates TBK1 to promote its oligomerization and type I IFN production, and methylates EZH2 R342 to stabilize PRC2 and repress P16/P21.

    Evidence ChIP-seq, histone-binding assay, CRC mouse model (SMARCA4); AUC, native PAGE, mutagenesis (dimerization); subcellular fractionation, siRNA rescue (SCYL1); myeloid KO mice, viral challenge (TBK1); mutagenesis, Co-IP, xenograft (EZH2-PRC2)

    PMID:32583741 PMID:33853662 PMID:34551290 PMID:34688662 PMID:34775498

    Open questions at the time
    • Crystal structure of SMARCA4 bound to H4R3me2a peptide not available
    • Whether PRMT1 Golgi function is independent of its nuclear role unclear
  9. 2022 High

    PRMT1 was established as a regulator of lineage-specific transcription through androgen receptor enhancer binding in prostate cancer; it also methylates BRD4 (antagonized by JMJD6 demethylase) and SOX2 to promote cancer stemness.

    Evidence Genome-scale CRISPR screen with ChIP-seq (AR); Co-IP, in vitro methylation and demethylation assay (BRD4); GST pulldown, PDX model (SOX2)

    PMID:35196489 PMID:36377249 PMID:37737256

    Open questions at the time
    • Whether PRMT1 methylates AR directly or acts solely through H4R3me2a at enhancers not resolved
    • JMJD6-PRMT1 antagonism at BRD4 not validated in vivo
  10. 2023 High

    PRMT1's roles in metabolism and innate immunity were defined: it methylates PHGDH at R236 to boost serine biosynthesis in HCC, methylates cGAS at R133 to block dimerization and suppress STING signaling, is relocated to the cytoplasm by CDK5-mediated S307 phosphorylation to methylate WDR24 and activate mTORC1, and methylates SRSF1 to control exon inclusion in breast cancer splicing programs.

    Evidence In vitro methylation, metabolomics, PDX model (PHGDH); cGAS dimerization assay, PRMT1 KO, IFN reporter, tumor immunity (cGAS); kinase assay, subcellular fractionation, xenograft (CDK5/WDR24); methylome profiling, splicing analysis, inhibitor (SRSF1)

    PMID:36823188 PMID:36995937 PMID:37193698 PMID:37938975

    Open questions at the time
    • How CDK5-PRMT1-mTORC1 axis interfaces with amino acid sensing machinery mechanistically unresolved
    • Whether cGAS methylation is constitutive or stimulus-dependent unclear
  11. 2024 High

    Upstream regulatory circuits were elaborated: FBXO7 ubiquitinates PRMT1 at K37 for degradation to suppress serine synthesis in HCC; LPCAT2-mediated acetylation of PRMT1 at K145 retains it in the cytoplasm to regulate ferroptosis; PRMT1 methylates multiple glycolytic enzymes (PHGDH, PFKFB3, PKM2, PGK1) to rewire carbon flux toward serine and lipid biosynthesis; and PRMT1 suppresses MHC-I expression by limiting STAT1.

    Evidence Ubiquitination assay with lysine mapping, CRC and HCC mouse models (FBXO7/LPCAT2); 13C metabolic flux analysis, IHC-imaging MS in clinical specimens (metabolic enzymes); CRISPR screen, flow cytometry, PRMT1 KO/inhibitor (MHC-I/STAT1)

    PMID:38383964 PMID:38401121 PMID:38402202 PMID:38605214 PMID:38839752 PMID:39009589

    Open questions at the time
    • How FBXO7 vs. TRIM48 vs. USP7 compete for PRMT1 protein level control in different tissues not understood
    • Structural basis of PRMT1 K145 acetylation affecting nuclear import unresolved
  12. 2025 Medium

    PRMT1 methylation of PARP1 was shown to dually promote DNA repair and NF-κB/P65-driven tumor stemness and immune evasion, highlighting PRMT1 as an integrator connecting genome integrity with immune signaling.

    Evidence Mass spectrometry, Co-IP, in vitro methylation, P65 signaling, metastasis assays in TNBC

    PMID:40927753

    Open questions at the time
    • Specific arginine sites on PARP1 methylated by PRMT1 not fully mapped
    • Whether PRMT1-PARP1 axis operates in normal tissue repair or is cancer-specific unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • A unifying model for how PRMT1 selects among its >30 known substrates in vivo—whether through adaptor proteins (BTG1/BTG2, GFI1), post-translational modifications (phosphorylation, acetylation), subcellular compartmentalization, or chromatin context—remains to be established, as does a comprehensive structural understanding of how oligomeric state, redox modification, and cofactor occupancy jointly regulate catalytic output.
  • No unified substrate-selection model exists
  • Full-length PRMT1 structure with substrates and cofactors not resolved
  • Tissue-specific PRMT1 interactome not systematically characterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 17 GO:0098772 molecular function regulator activity 4 GO:0042393 histone binding 3
Localization
GO:0005634 nucleus 6 GO:0005829 cytosol 2 GO:0005794 Golgi apparatus 1
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-392499 Metabolism of proteins 4 R-HSA-4839726 Chromatin organization 4 R-HSA-1430728 Metabolism 3 R-HSA-168256 Immune System 3 R-HSA-8953854 Metabolism of RNA 3 R-HSA-1640170 Cell Cycle 2 R-HSA-73894 DNA Repair 2
Partners
BTG2CDK5CSNK1A1DNA-PKCSFBXO7GFI1SMARCA4TRIM48

Evidence

Reading pass · 50 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 HRMT1L2 (human PRMT1) encodes a protein arginine methyltransferase that exhibits methyltransferase activity in vitro and can complement a yeast HMT1 mutant strain in vivo, establishing it as the human ortholog of yeast Hmt1p. In vitro methyltransferase assay with recombinant protein; yeast complementation assay Genomics High 9545638
2015 PRMT1 methylates RBM15 at R578, leading to its ubiquitylation by the E3 ligase CNOT4 and subsequent proteasomal degradation; this reduces RBM15 protein levels and alters alternative splicing of megakaryocytic genes (GATA1, RUNX1, TAL1, c-MPL) by displacing the splicing factor SF3B1 from intronic regions. Co-IP, in vitro methylation assay, mass spectrometry, RNA-seq, ChIP, overexpression/knockdown in leukemia cell lines eLife High 26575292
2015 PRMT1 methylates EGFR at R198 and R200 in the extracellular domain, enhancing EGF binding, receptor dimerization, and downstream signaling activation; methylation-defective EGFR reduces tumor growth in orthotopic models and increased methylation confers resistance to cetuximab. In vitro methylation assay, site-directed mutagenesis, mouse xenograft model, mass spectrometry The Journal of clinical investigation High 26571401
2015 PRMT1 enzymatic activity is regulated by oxidation: H2O2 oxidizes one or more cysteine residues of PRMT1 to sulfenic acid, impairing methyltransferase activity in a concentration-dependent and reversible manner. In vitro methyltransferase activity assay, chemical modification with H2O2, reduction rescue experiments The Journal of biological chemistry High 25911106
2017 PRMT1 methylates CDK4, preventing formation of the CDK4–Cyclin-D3 complex and thereby inducing cell cycle arrest in pre-B cells; BTG2 acts together with PRMT1 in this module to limit pre-B cell expansion and suppress leukemogenesis. Co-IP, in vitro methylation assay, cell cycle analysis, in vivo pre-B cell leukemia model Nature immunology High 28628091
2018 PRMT1 interacts with and methylates CaMKII at R9 and R275, leading to inhibition of CaMKII activity; cardiac-specific PRMT1 ablation causes CaMKII hyperactivation, dilated cardiomyopathy, and heart failure, rescued by pharmacological CaMKII inhibition. Cardiac-specific knockout mice, Co-IP, in vitro methylation assay, site-directed mutagenesis, pharmacological rescue Nature communications High 30504773
2018 PRMT1 facilitates TGF-β signaling by methylating SMAD7 at the TGF-β receptor complex, promoting SMAD7 dissociation from the receptor and enabling SMAD3 activation, thereby driving epithelial-to-mesenchymal transition and epithelial stem-cell generation. In vitro methylation assay, Co-IP, PRMT1 depletion with functional EMT readouts, receptor complex analysis The Journal of biological chemistry High 29907569
2018 GFI1 interacts with PRMT1 and enables PRMT1 to bind and methylate MRE11 and 53BP1, modifications required for their function in the DNA damage response; GFI1 deletion causes hypersensitivity to ionizing radiation due to impaired PRMT1-mediated methylation of these repair proteins. Co-IP, in vitro methylation assay, GFI1 knockout cells, ionizing radiation sensitivity assay Nature communications High 29651020
2017 PRMT1 methylates the RGG motif of UBAP2L, and increased arginine methylation of UBAP2L blocks its interaction with stress granule (SG) components, while decreased methylation promotes SG assembly; UBAP2L is thus regulated by PRMT1 to control stress granule dynamics. Co-IP, in vitro methylation assay, live-cell imaging, overexpression/knockdown of PRMT1 and UBAP2L Cell death and differentiation High 31114027
2019 Skeletal muscle-specific PRMT1 deletion causes muscle atrophy; in the absence of PRMT1, PRMT6 levels increase and specifically methylates FOXO3 at R188 and R249, activating FOXO3 and upregulating atrogenes TRIM63 and FBXO32; PRMT6 depletion abrogates FOXO3 hyperactivation in PRMT1-deficient muscle. Conditional knockout mice, adenoviral shRNA, in vitro methylation assay, epistasis (PRMT6 depletion rescue) Autophagy High 30653406
2017 PRMT1 methylates the co-activator Eya1; loss of PRMT1 in muscle stem cells prevents Eya1 methylation and reduces its recruitment to the MyoD promoter, impairing MyoD expression and blocking myogenic differentiation. Pax7CreERT2 conditional PRMT1 KO, in vitro methylation assay, ChIP, muscle regeneration assay Molecular and cellular biology High 27849571
2017 CSNK1a1 kinase directly phosphorylates PRMT1, controlling PRMT1 genomic targeting to proliferation genes and differentiation-suppressing genes (including GRHL3); this cooperation between CSNK1a1 and PRMT1 maintains epidermal progenitor self-renewal. Mass spectrometry interactome, Co-IP, kinase assay, mouse knockout, ChIP-seq, mosaic human epidermis regeneration Developmental cell High 28943242
2017 TRIM48 promotes K48-linked polyubiquitination and degradation of PRMT1; PRMT1 negatively regulates ASK1 by enhancing its interaction with thioredoxin (Trx); thus TRIM48 activates ASK1 by relieving PRMT1-mediated suppression. Pulldown screen, Co-IP, ubiquitination assay, ASK1 kinase assay, TRIM48 knockdown/overexpression Cell reports High 29186683
2020 DNA-PK binds to and phosphorylates PRMT1 in response to cisplatin, inducing PRMT1 chromatin recruitment and redirecting its enzymatic activity to deposit H4R3me2a at pro-inflammatory gene promoters, driving the senescence-associated secretory phenotype. MS-based proteomics, Co-IP, ChIP, kinase assay, cisplatin treatment Cell reports High 31995759
2021 PRMT1-mediated H4R3me2a histone mark directly recruits SMARCA4 (an ATPase subunit of the SWI/SNF complex) to promote transcription of EGFR and TNS4, enhancing colorectal cancer proliferation and migration. Co-IP, ChIP-seq, biochemical histone binding assay, cell viability/migration assays, in vivo CRC mouse model Genome medicine High 33853662
2021 PRMT1 promotes TBK1 activation by catalyzing asymmetric dimethylation of R54, R134, and R228 on TBK1, which enhances TBK1 oligomerization after viral infection and promotes downstream type I interferon production; myeloid-specific Prmt1 KO mice are more susceptible to viral infection. In vitro methylation assay, Co-IP, TBK1 oligomerization assay, myeloid-specific KO mice, viral challenge Cell reports High 34551290
2020 PRMT1 asymmetrically dimethylates EZH2 at R342 (meR342-EZH2), which inhibits CDK1-mediated phosphorylation of EZH2 at T345 and T487, thereby attenuating TRAF6-mediated EZH2 ubiquitylation and increasing EZH2 stability to promote breast cancer EMT and metastasis. In vitro methylation assay, site-directed mutagenesis, Co-IP, ubiquitination assay, in vivo xenograft Cell death and differentiation High 32895488
2019 PRMT1 methylates C/EBPα at R35, R156, and R165; this methylation blocks the interaction of C/EBPα with its corepressor HDAC3, promoting cyclin D1 expression and breast cancer cell proliferation. Tandem affinity purification/mass spectrometry, Co-IP, in vitro methylation, site-directed mutagenesis, RNA-seq Cancer research High 31015230
2019 PRMT1 constitutively associates with IGF-1R and becomes activated upon IGF-1 stimulation; activated PRMT1 methylates ERα at R260, inducing formation of the mERα/Src/PI3K complex and propagating non-genomic IGF-1 signaling in breast cancer cells. Co-IP, in vitro methylation assay, PRMT1 inhibition (pharmacological and knockdown), signaling assays Oncogene High 30692633
2019 PRMT1 methylates SMAD7 arginine residues at the TGF-β receptor complex, promoting SMAD7 dissociation and enabling SMAD3-mediated downstream signaling; similar mechanism operates for BMP-induced SMAD6 methylation. In vitro methylation assay, receptor complex Co-IP, PRMT1 knockdown, EMT functional assays The Journal of biological chemistry High 29907569
2023 PRMT1 methylates PHGDH at R236, enhancing its catalytic activity to promote serine biosynthesis, which ameliorates oxidative stress and supports HCC tumor growth; a non-methylatable TAT-tagged peptide blocking PHGDH methylation inhibits HCC in PDX models. In vitro methylation assay, PHGDH enzymatic activity assay, metabolomics, site-directed mutagenesis, PDX tumor model Nature communications High 36823188
2024 FBXO7 E3 ubiquitin ligase binds PRMT1, ubiquitinates it at K37, and promotes its proteasomal degradation, thereby suppressing PRMT1-mediated PHGDH methylation and serine synthesis in HCC. Co-IP, ubiquitination assay, site-directed mutagenesis, proteasome inhibitor treatment, in vivo HCC models Nature communications High 38839752
2023 PRMT1 methylates cGAS at the conserved R133 residue, preventing cGAS dimerization and suppressing cGAS/STING innate immune signaling in cancer cells; PRMT1 ablation or inhibition restores cGAS/STING signaling, elevates interferon responses, and enhances anti-tumor immunity. In vitro methylation assay, cGAS dimerization assay, PRMT1 KO/inhibitor, type I/II IFN reporter assays, in vivo tumor immune infiltration Nature communications High 37193698
2021 PRMT1-mediated meR342-EZH2 methylation promotes PRC2 assembly by preventing AMPKα1-mediated pT311-EZH2 phosphorylation, enhancing EZH2-SUZ12 interaction, and repressing P16 and P21 transcription to promote breast cancer cell proliferation. In vitro methylation, Co-IP, site-directed mutagenesis, ChIP, cell cycle analysis, xenograft Cell death & disease High 34775498
2021 PRMT1 regulates SCYL1 arginine methylation at the γ2-COP-binding site, which is required for SCYL1 interaction with γ2-COP and COPI vesicle formation; PRMT1 co-localizes with SCYL1 in the Golgi fraction, and PRMT1 inhibition disrupts Golgi morphology, axon outgrowth, and dendrite complexity. In vitro methylation assay, Co-IP, subcellular fractionation, siRNA rescue with methylation-site mutant, Golgi morphology imaging Molecular biology of the cell High 32583741
2021 PRMT1 suppresses MHC-I surface expression by limiting STAT1 expression and activation; PRMT1 knockout or type I PRMT inhibition enhances IFN-γ-induced MHC-I expression, and PRMT1 re-introduction reverses this effect. CRISPR-Cas9 screen, PRMT1 KO, pharmacological inhibition (GSK3368715), flow cytometry for MHC-I, STAT1 activity assays Cell reports High 38401121
2022 PRMT1 regulates androgen receptor (AR) recruitment to genomic target sites; PRMT1 inhibition impairs AR binding at lineage-specific enhancers, decreasing expression of AR target oncogenes including AR itself in prostate cancer. Genome-scale CRISPR-Cas9 screen, ChIP-seq, PRMT1 KO/inhibition, AR target gene expression Cell reports High 35196489
2023 CDK5 phosphorylates PRMT1 at S307, promoting PRMT1 translocation from nucleus to cytoplasm and lysosome in response to amino acids; cytoplasmic PRMT1 then methylates WDR24, an essential GATOR2 component, to activate mTORC1 signaling and promote tumor growth. Co-IP, kinase assay, subcellular fractionation, in vitro methylation assay, site-directed mutagenesis, xenograft Cell reports High 36995937
2021 PRMT1 ablation in vascular smooth muscle cells (VSMCs) causes aortic dissection by downregulating contractile gene expression; PRMT1 directly regulates myocardin gene activation through modulation of H4R3me2a epigenetic histone marks at the myocardin promoter. VSMC-specific conditional KO mice, ChIP, ex vivo aortic contractility assay, gene expression profiling Experimental & molecular medicine High 34635781
2020 PRMT1 regulates epicardial EMT and invasion by controlling splicing of Mdm4; loss of PRMT1 leads to p53 accumulation that enhances Slug degradation and blocks EMT, establishing a PRMT1-p53 pathway required for epicardial lineage formation. Epicardial-specific Prmt1 KO, scRNA-seq, Mdm4 splicing analysis, p53 and Slug protein analysis Cell reports High 32521264
2019 PRMT1 is required for maintenance of mature β-cell identity; its deletion causes immediate loss of H4R3me2a and subsequent reduction in chromatin accessibility at binding sites for CTCF and β-cell transcription factors, leading to diabetes. β-cell-specific PRMT1 KO, ChIP-seq, ATAC-seq, H4R3me2a histone mark analysis Diabetes High 31848151
2023 PRMT1 methylates SRSF1 at arginine residues; this methylation is critical for SRSF1 phosphorylation, RNA binding, and exon inclusion; PRMT1 overexpression promotes aberrant exon inclusion in breast cancer, and PRMT1 inhibition with iPRMT1 blocks this splicing program. In vitro methylation assay, PRMT1 methylome profiling, RNA splicing analysis, PRMT1 inhibitor treatment Cell reports High 37938975
2017 Kinetic analysis reveals PRMT1 operates by a sequential ordered Bi-Bi mechanism; the perceived degree of processivity depends on both cofactor and enzyme concentration, and substrate sequence influences kinetic parameters. Steady-state enzyme kinetics, varied substrate and cofactor concentrations, synthetic peptides Chembiochem High 29112789
2021 Cancer-associated mutations W215L, Y220N, and M224V in the PRMT1 dimerization arm disrupt oligomer formation and substantially impair both SAM binding and methyltransferase activity, as shown by AUC, native PAGE, and activity assays. Site-directed mutagenesis, analytical ultracentrifugation, native PAGE, in vitro methyltransferase activity assay, molecular dynamics simulations The Journal of biological chemistry High 34688662
2017 BTG1 interacts with ATF4 and recruits PRMT1 to methylate ATF4 at R239, positively modulating ATF4 transcriptional activity and stress response; loss of BTG1 impairs this modification and provides a survival advantage under cellular stress. Co-IP, in vitro methylation assay, Btg1 knockout MEFs, stress survival assay Oncotarget Medium 26657730
2023 PRMT1 methylates WTAP at arginine residues; this promotes WTAP activity as a component of the m6A methyltransferase complex, leading to m6A modification of NDUFS6 mRNA, upregulation of oxidative phosphorylation, and multiple myeloma tumorigenesis. Co-IP, in vitro methylation assay, m6A-seq/MeRIP, PRMT1 knockdown, cell proliferation assays Cell death & disease Medium 37558663
2024 PRMT1 methylates PHGDH at R54 or R20 in TNBC cells, activating PHGDH enzymatic activity by stabilizing 3-phosphoglycerate binding and suppressing polyubiquitination; concurrently, PRMT1 methylates PFKFB3 and PKM2, diverting glucose toward serine synthesis pathways and increasing palmitate production via FASN to drive chemoresistance. In vitro methylation assay, 13C metabolic flux analysis, site-directed mutagenesis, IHC with imaging MS in clinical specimens Cancer research High 38383964
2024 PRMT1 induces arginine methylation of DDX3, enhancing its protein stability by preventing proteasomal degradation; DDX3 then translocates to mitochondria and facilitates PINK1 translation to coordinate mitophagy and mitochondrial biogenesis, supporting breast cancer metastasis. Co-IP, in vitro methylation assay, proteasome inhibitor treatment, mitochondrial fractionation, PINK1 translation assay Cancer research High 39042374
2024 PRMT1 methylates PGK1 at R206, which enhances phosphorylation of PGK1 at S203, inhibiting mitochondrial function and promoting glycolysis in colorectal cancer. In vitro methylation assay, site-directed mutagenesis, phosphorylation analysis, metabolic assays Cell death & disease Medium 38402202
2020 PRMT1 methylates SMARCA4R1157W mutant more efficiently than WT SMARCA4 due to enhanced SMARCA4 recruitment to H4R3me2a; the R1157W mutation in SMARCA4 facilitates chromatin remodeling by enhancing its ATPase activity within the SWI/SNF complex. Co-IP, ChIP, ATPase activity assay, CRISPR mutation introduction, CRC cell and PDX organoid assays NPJ precision oncology Medium 36922568
2023 PRMT1 methylates c-Fos at R287; this modification protects c-Fos from autophagic degradation, stabilizing c-Fos protein and enhancing AP-1 transcriptional activity to promote gastric tumorigenesis. Co-IP, in vitro methylation assay, site-directed mutagenesis, autophagy inhibition, AP-1 reporter assay International journal of biological sciences Medium 37564212
2022 PRMT1 methylates BRD4 at R179/181/183 (antagonized by demethylase JMJD6), and this methylation promotes BRD4 phosphorylation; BRD4 methylation is also associated with TGF-β signaling and ovarian cancer invasion. Co-IP, in vitro methylation assay, site-directed mutagenesis, JMJD6 demethylation assay Cell death & disease Medium 37737256
2022 PRMT1 directly interacts with and methylates SOX2; EphA2 increases PRMT1 expression and activity, and PRMT1-mediated SOX2 methylation induces cancer stemness and chemoresistance in SCLC. Co-IP, GST pulldown, in vitro methylation assay, EphA2 mutant analysis, PDX model Cancer science Medium 36377249
2020 PRMT1 methylates progesterone receptor (PR) at R637, reducing PR stability and accelerating its recycling, thereby increasing PR transcriptional activity and expression of progesterone-inducible genes in breast cancer cells. Co-IP, in vitro methylation assay, site-directed mutagenesis, PRMT1 depletion, PR target gene analysis iScience Medium 32563156
2024 PRMT1 promotes glycolysis (Warburg effect) in NSCLC by upregulating PTBP1, which increases the PKM2/PKM1 ratio; p53 activation under glucose-deficient conditions suppresses USP7 and thereby promotes polyubiquitin-dependent degradation of PRMT1. PRMT1 knockdown/overexpression, PTBP1 and PKM splicing analysis, USP7 inhibitor, p53 activation assays Cell death & disease Medium 39009589
2021 PRMT1 methylates STAT3 at R688; TIPE1 binds to the catalytic domain of PRMT1 and inhibits this methylation, thereby decreasing STAT3 transactivation and suppressing osteosarcoma malignancy. Co-IP, in vitro methylation assay, TIPE1 overexpression, STAT3 reporter assay Cell death & disease Medium 36151091
2025 PRMT1 methylates PARP1, which on one hand promotes PARP1-mediated DNA damage repair; on the other hand, it modulates NF-κB signaling via P65 activation to enhance tumor stemness and immune suppression, driving lung metastasis and chemoresistance in TNBC. Mass spectrometry, Co-IP, in vitro methylation assay, P65 signaling analysis, functional metastasis assays Research (Washington, D.C.) Medium 40927753
2018 RANKL treatment increases PRMT1 expression and nuclear localization in bone marrow-derived macrophages in a JNK-dependent manner; PRMT1 regulates NF-κB transcriptional activity by directly interacting with NF-κB subunit p65, promoting osteoclastogenesis. siRNA knockdown, Co-IP (PRMT1-p65), RANKL signaling assays, haploinsufficient mice, in vivo OVX bone loss model Experimental & molecular medicine Medium 30154485
2008 TR3 orphan receptor physically interacts with PRMT1 through the catalytic domain and inhibits PRMT1 methyltransferase activity; reciprocally, PRMT1 binding stabilizes TR3 protein and enhances its transcriptional activity independently of methyltransferase activity. Co-IP, in vitro methyltransferase activity inhibition assay, TR3 knockdown/KO cells, luciferase reporter Nucleic acids research Medium 19095693
2024 LPCAT2 arrests PRMT1 in the cytoplasm of CRC cells by regulating acetylation of PRMT1 at K145, thereby preventing nuclear PRMT1-mediated SLC7A11 transcriptional activation and inducing ferroptosis. scRNA-seq, Co-IP, acetylation analysis, PRMT1 localization fractionation, PRMT1 knockout mice CRC model Oncogene Medium 38605214

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. eLife 157 26575292
1998 Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 152 9545638
2020 Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell death and differentiation 141 32895488
2015 PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. The Journal of clinical investigation 128 26571401
2009 The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacological research 113 19643181
2021 PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome medicine 111 33853662
2023 PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nature communications 108 36823188
2019 Skeletal muscle-specific Prmt1 deletion causes muscle atrophy via deregulation of the PRMT6-FOXO3 axis. Autophagy 103 30653406
2021 Structure, Activity, and Function of PRMT1. Life (Basel, Switzerland) 95 34833023
2008 Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. American journal of physiology. Gastrointestinal and liver physiology 80 18174275
2019 UBAP2L arginine methylation by PRMT1 modulates stress granule assembly. Cell death and differentiation 77 31114027
2018 Cardiac specific PRMT1 ablation causes heart failure through CaMKII dysregulation. Nature communications 73 30504773
2023 PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity. Nature communications 67 37193698
2019 Methylation of C/EBPα by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer. Cancer research 66 31015230
2018 Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation. The Journal of biological chemistry 65 29907569
2013 CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie 63 24211191
2017 Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models. Scientific reports 60 28638106
2017 TRIM48 Promotes ASK1 Activation and Cell Death through Ubiquitination-Dependent Degradation of the ASK1-Negative Regulator PRMT1. Cell reports 59 29186683
2017 CSNK1a1 Regulates PRMT1 to Maintain the Progenitor State in Self-Renewing Somatic Tissue. Developmental cell 58 28943242
2024 FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma. Nature communications 55 38839752
2017 Arginine Methylation by PRMT1 Regulates Muscle Stem Cell Fate. Molecular and cellular biology 55 27849571
2006 Haem carrier protein 1 (HCP1): Expression and functional studies in cultured cells. FEBS letters 55 17156779
2020 PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin. Cell reports 53 31995759
2020 PRMT1-p53 Pathway Controls Epicardial EMT and Invasion. Cell reports 53 32521264
2012 Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia. Journal of hematology & oncology 53 22839530
2021 PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell death & disease 52 34775498
2018 GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nature communications 52 29651020
2021 PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics 49 33859753
2010 The putative heme transporter HCP1 is expressed in cultured astrocytes and contributes to the uptake of hemin. Glia 49 19533605
2019 Deep Protein Methylation Profiling by Combined Chemical and Immunoaffinity Approaches Reveals Novel PRMT1 Targets. Molecular & cellular proteomics : MCP 48 31451547
2009 Characterization of PRMT1 from Plasmodium falciparum. The Biochemical journal 48 19344311
2024 PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis. Cell death & disease 45 38402202
2017 The BTG2-PRMT1 module limits pre-B cell expansion by regulating the CDK4-Cyclin-D3 complex. Nature immunology 44 28628091
2015 Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity. The Journal of biological chemistry 43 25911106
2024 PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer. Cancer research 42 38383964
2017 Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation. Nature communications 42 29026071
2023 PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6. Cell death & disease 40 37558663
2021 The protein arginine methyltransferase PRMT1 promotes TBK1 activation through asymmetric arginine methylation. Cell reports 39 34551290
2019 The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer. Oncogene 39 30692633
2008 A feedback regulatory loop between methyltransferase PRMT1 and orphan receptor TR3. Nucleic acids research 37 19095693
2014 The role of hepcidin, ferroportin, HCP1, and DMT1 protein in iron absorption in the human digestive tract. Przeglad gastroenterologiczny 36 25276251
2023 The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer. NPJ precision oncology 35 36922568
2017 Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress. International journal of molecular sciences 34 28671608
2016 Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress. Oncotarget 34 26657730
2022 A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell reports 33 35196489
2020 PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells. DNA repair 33 32861926
2020 LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis. Cell cycle (Georgetown, Tex.) 32 32420808
2023 PRMT1 driven PTX3 regulates ferritinophagy in glioma. Autophagy 31 36647288
2023 Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesis. Cell reports 30 37938975
2022 Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. The Journal of clinical investigation 30 35040433
2021 Inducible Prmt1 ablation in adult vascular smooth muscle leads to contractile dysfunction and aortic dissection. Experimental & molecular medicine 30 34635781
2020 Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling. International journal of molecular sciences 30 32357521
2020 PRMT1 promotes neuroblastoma cell survival through ATF5. Oncogenesis 30 32415090
2022 PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers 29 35053470
2020 Roles of protein arginine methyltransferase 1 (PRMT1) in brain development and disease. Biochimica et biophysica acta. General subjects 29 33127433
2020 Macrophages-stimulated PRMT1-mediated EZH2 methylation promotes breast cancer metastasis. Biochemical and biophysical research communications 28 33092789
2024 PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma. Cancer research 27 37991725
2024 Arginine Methylation of DDX3 by PRMT1 Mediates Mitochondrial Homeostasis to Promote Breast Cancer Metastasis. Cancer research 27 39042374
2023 Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis. International journal of biological sciences 27 37564212
2023 CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth. Cell reports 26 36995937
2020 Anti-platelet adhesion and in situ capture of circulating endothelial progenitor cells on ePTFE surface modified with poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) and hemocompatible peptide 1 (HCP-1). Colloids and surfaces. B, Biointerfaces 26 32447201
2019 PRMT1 Is Required for the Maintenance of Mature β-Cell Identity. Diabetes 26 31848151
2022 Protein arginine methyltransferase PRMT1 promotes adipogenesis by modulating transcription factors C/EBPβ and PPARγ. The Journal of biological chemistry 25 35921899
2021 Melatonin Inhibits Osteoclastogenesis and Bone Loss in Ovariectomized Mice by Regulating PRMT1-Mediated Signaling. Endocrinology 25 33713122
2024 PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Cell reports. Medicine 24 38460517
2023 Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion. Cell death & disease 24 37737256
2022 Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation. Cancer science 24 36377249
2018 Structural basis for the pathogenesis of Campylobacter jejuni Hcp1, a structural and effector protein of the Type VI Secretion System. The FEBS journal 24 30194714
2024 PRMT1 in human neoplasm: cancer biology and potential therapeutic target. Cell communication and signaling : CCS 23 38326807
2020 PRMT1 Is Critical for the Transcriptional Activity and the Stability of the Progesterone Receptor. iScience 23 32563156
2018 PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice. Experimental & molecular medicine 23 30154485
2021 Arginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer. Life (Basel, Switzerland) 22 34440533
2022 TIPE1 inhibits osteosarcoma tumorigenesis and progression by regulating PRMT1 mediated STAT3 arginine methylation. Cell death & disease 21 36151091
2021 Depletion of Prmt1 in Adipocytes Impairs Glucose Homeostasis in Diet-Induced Obesity. Diabetes 21 34039627
2017 Kinetic Analysis of PRMT1 Reveals Multifactorial Processivity and a Sequential Ordered Mechanism. Chembiochem : a European journal of chemical biology 21 29112789
2024 PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity. Cell reports 20 38401121
2023 PRMT1 promotes the proliferation and metastasis of gastric cancer cells by recruiting MLXIP for the transcriptional activation of the β-catenin pathway. Genes & diseases 20 37554218
2019 Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells. Scientific reports 20 30741995
2015 Transcriptome analysis of Burkholderia pseudomallei T6SS identifies Hcp1 as a potential serodiagnostic marker. Microbial pathogenesis 20 25616255
2024 LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis. Oncogene 19 38605214
2021 The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine 19 34516499
2020 SCYL1 arginine methylation by PRMT1 is essential for neurite outgrowth via Golgi morphogenesis. Molecular biology of the cell 19 32583741
2018 Overexpressing PRMT1 Inhibits Proliferation and Invasion in Pancreatic Cancer by Inverse Correlation of ZEB1. IUBMB life 19 30194893
2024 PRMT1 promotes Warburg effect by regulating the PKM2/PKM1 ratio in non-small cell lung cancer. Cell death & disease 18 39009589
2021 Silencing circRNA LRP6 down-regulates PRMT1 to improve the streptozocin-induced pancreatic β-cell injury and insulin secretion by sponging miR-9-5p. Journal of bioenergetics and biomembranes 18 33826088
2021 Naturally occurring cancer-associated mutations disrupt oligomerization and activity of protein arginine methyltransferase 1 (PRMT1). The Journal of biological chemistry 18 34688662
2017 Discovery of Decamidine as a New and Potent PRMT1 Inhibitor. MedChemComm 18 28649316
2017 Physiological stress-induced corticosterone increases heme uptake via KLF4-HCP1 signaling pathway in hippocampus neurons. Scientific reports 17 28720846
2017 Design and synthesis of novel PRMT1 inhibitors and investigation of their binding preferences using molecular modelling. Bioorganic & medicinal chemistry letters 17 28927791
2025 PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer. Research (Washington, D.C.) 16 40927753
2018 Detection of PRMT1 inhibitors with stopped flow fluorescence. Signal transduction and targeted therapy 16 29535867
2018 Protein Arginine Methyltransferase PRMT1 Is Essential for Palatogenesis. Journal of dental research 16 29986157
2016 Lactate induced HIF-1α-PRMT1 cross talk affects MHC I expression in monocytes. Experimental cell research 16 27521225
2003 Characterization of a novel barley protein, HCP1, that interacts with the Brome mosaic virus coat protein. Molecular plant-microbe interactions : MPMI 16 12744464
2025 Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibit gastric cancer based on WGCNA and machine algorithms. Phytomedicine : international journal of phytotherapy and phytopharmacology 15 40446574
2024 Role of PRMT1 and PRMT5 in Breast Cancer. International journal of molecular sciences 15 39201539
2023 Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation. Bone reports 15 37593409
2022 Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (PRMT1) Gene, Expressed in Breast Cancer Cells. Genes 15 35885916
2021 Melioidosis Patient Survival Correlates With Strong IFN-γ Secreting T Cell Responses Against Hcp1 and TssM. Frontiers in immunology 15 34394091
2022 Functional Study of Leishmania braziliensis Protein Arginine Methyltransferases (PRMTs) Reveals That PRMT1 and PRMT5 Are Required for Macrophage Infection. ACS infectious diseases 14 35226477